Abciximab C₂₂H₂₇ClN₄O₃S

Therapeutic indications

Abciximab is indicated for:

Unstable angina

Population group: both men and women, only adults (18 years old or older)

Abciximab is indicated as an adjunct to heparin and acetylsalicylic acid for the short-term (1-month) reduction of the risk of myocardial infarction, in patients with unstable angina, not responding to full conventional therapy who have been scheduled for percutaneous coronary intervention.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Percutaneous coronary intervention

Population group: both men and women, only adults (18 years old or older)

Abciximab is indicated as an adjunct to heparin and acetylsalicylic acid for the prevention of ischaemic cardiac complications in patients undergoing percutaneous coronary intervention (PCI: balloon angioplasty, atherectomy, and stent).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Abciximab is contraindicated in the following cases:

Thrombocytopenia

Thrombocytopenic disorder (disorder)

Severe renal failure, dialysis

at least one of
Hemodialysis (procedure)
Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Active internal bleeding

Bleeding (finding)

History of cerebrovascular accident within two years

History of cerebrovascular accident (situation)

Severe hepatic failure

Hepatic failure stage IV

Vasculitis

Vasculitis (disorder)

Severe uncontrolled hypertension

Arteriovenous malformation, aneurysm

at least one of
Congenital arteriovenous malformation (disorder)
Aneurysm (disorder)

Recent (within two months) major surgery

Surgical procedure (procedure)

Intracranial neoplasm

Intracranial tumor (disorder)

Hypertensive retinopathy

Hypertensive retinopathy (disorder)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2016: REOPRO Solution for injection or infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈